Home > Publications database > Radiomics-based prediction of HCC response to atezolizumab/bevacizumab > print

001     304101
005     20250828140036.0
024 7 _ |a 10.3892/ol.2025.15229
|2 doi
024 7 _ |a 1792-1074
|2 ISSN
024 7 _ |a 1792-1082
|2 ISSN
037 _ _ |a DKFZ-2025-01769
082 _ _ |a 610
100 1 _ |a Rodriguez, Isaac
|b 0
245 _ _ |a Radiomics-based prediction of HCC response to atezolizumab/bevacizumab
260 _ _ |a Athens
|c 2025
|b Spandidos Publ.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1756382409_18470
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: inrepo02.dkfz.de
700 1 _ |a Vellala, Abhinay
|b 1
700 1 _ |a Itzel, Timo
|b 2
700 1 _ |a Daza, Jimmy
|b 3
700 1 _ |a Vácha, Michael
|b 4
700 1 _ |a Chang, De-Hua
|b 5
700 1 _ |a Debic, Manuel
|b 6
700 1 _ |a Dill, Michael
|0 P:(DE-He78)54a6641a6c26ddc49cc754740e90b438
|b 7
|u dkfz
700 1 _ |a Seidensticker, Max
|b 8
700 1 _ |a Mayerle, Julia
|b 9
700 1 _ |a Munker, Stefan
|b 10
700 1 _ |a Schoenberg, Stefan
|b 11
700 1 _ |a Müller, Lukas
|b 12
700 1 _ |a Galle, Peter
|b 13
700 1 _ |a Weinmann, Arndt
|b 14
700 1 _ |a Tamandl, Dietmar
|b 15
700 1 _ |a Pinter, Matthias
|b 16
700 1 _ |a Scheiner, Bernhard
|b 17
700 1 _ |a Weiss, Christel
|b 18
700 1 _ |a Pech, Maciej
|b 19
700 1 _ |a Sinner, Friedrich
|b 20
700 1 _ |a Keitel, Verena
|b 21
700 1 _ |a Venerito, Marino
|b 22
700 1 _ |a Ebert, Matthias
|b 23
700 1 _ |a Teufel, Andreas
|b 24
700 1 _ |a Froelich, Matthias
|b 25
773 _ _ |a 10.3892/ol.2025.15229
|g Vol. 30, no. 4, p. 1 - 12
|0 PERI:(DE-600)2573196-8
|n 4
|p 484
|t Oncology letters
|v 30
|y 2025
|x 1792-1074
909 C O |p VDB
|o oai:inrepo02.dkfz.de:304101
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)54a6641a6c26ddc49cc754740e90b438
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ONCOL LETT : 2022
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-18
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-18
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-18
920 1 _ |0 I:(DE-He78)D500-20160331
|k D500
|l NWG Experimentelle Hepatologie, Entzündung und Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D500-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21